EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Biomarker‐Based Classification of Corticobasal Syndrome

Carla Palleis iD, Alexander Maximilian Bernhardt iD, Endy Weidinger, Urban M Fietzek, Alexander Jäck, Sabrina Katzdobler iD, Johannes Gnörich, Theresa Bauer, Nicolai Franzmeier, Robert Perneczky, German Imaging Initiative for Tauopathies (GII4T), Matthias Brendel iD und 2 weitere

Movement Disorders · 2026-01 · 41 (1) · 129-142

DOI: 10.1002/mds.70070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 06.10.2025. Verfasst von Carla Palleis und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany. Hauptthemen laut MEDLINE: Corticobasal Degeneration. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Alzheimer Forschung Initiative, German Center for Neurodegenerative Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Corticobasal syndrome (CBS) is a clinically defined syndrome with progressive movement and cortical dysfunction, caused by various underlying pathologies, most commonly tau‐predominant pathologies such as progressive supranuclear palsy and corticobasal degeneration, or Alzheimer's disease (AD). Lewy‐type α‐synucleinopathies (LTS), TDP‐43 proteinopathies, and mixed pathologies may also underlie CBS. The clinical impact of these pathologies remains poorly understood.

Objectives

To subclassify CBS patients in vivo using biomarkers for amyloid‐β (Aβ), Tau, and α‐synuclein (αSyn), and assess the clinical relevance of this stratification.

Methods

We conducted a prospective cohort study of 50 CBS patients at LMU University Hospital Munich. Biomarker analysis included cerebrospinal fluid (CSF) Aβ42 and Aβ42/40, [ 18 F]flutemetamol Aβ‐PET, [ 18 F]PI‐2620 tau‐PET, and αSyn seed amplification assays in CSF. CSF neurofilament light chain (NfL) served as a marker of neurodegeneration. Patients were stratified into six groups based on biomarker positivity.

Results

Tau positivity was found in 90% of CBS cases, Aβ in 28%, and αSyn in 24%. Stratification identified: 52% consistent with tau‐predominant pathology, 18% with AD, 10% with AD+LTS, 10% with tau‐predominant+LTS, 4% with isolated LTS, and 6% unclassified. αSyn positivity was more frequent in AD‐CBS (36%) than in tau‐predominant‐CBS (16%). Aβ‐positive cases showed greater cognitive impairment; Tau positivity correlated with worse motor symptoms; αSyn‐positive patients had milder motor symptoms, slower progression, and lower NfL levels.

Conclusions

CBS is molecularly heterogeneous. Biomarker‐based classification may enhance diagnostic precision and support personalized therapeutic strategies. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Corticobasal DegenerationHumansMaleFemaleAgedBiomarkersAmyloid beta-PeptidesMiddle Agedtau ProteinsPositron-Emission Tomographyalpha-SynucleinProspective StudiesPeptide FragmentsAged, 80 and over

Stichwörter der Autor:innen

proteinopathiestau‐PETα‐synuclein seed amplification assayβ‐amyloid

Substanzen

BiomarkersAmyloid beta-Peptidestau Proteinsalpha-SynucleinPeptide Fragmentsamyloid beta-protein (1-42)

Autor:innen und Institutionen

  • Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
  • Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
  • Schön Klinik München Schwabing, Munich, Germany.
  • Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
  • Institute for Stroke and Dementia Research (ISD), LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.

ORCID-Profile: Carla Palleis, Alexander Maximilian Bernhardt, Sabrina Katzdobler, Matthias Brendel

Förderung

  • Deutsche Forschungsgemeinschaft
  • Alzheimer Forschung Initiative
  • German Center for Neurodegenerative Diseases
  • German Parkinson's Association
  • Alzheimer Forschung Initiative e.V.
  • Munich Cluster for Systems Neurology
  • German Ministry of Research and Education
  • NOMIS Foundation

Zitieren

APA

Palleis, C., Bernhardt, A. M., Weidinger, E., Fietzek, U. M., Jäck, A., Katzdobler, S., Gnörich, J., Bauer, T., Franzmeier, N., Perneczky, R., German Imaging Initiative for Tauopathies (GII4T), Brendel, M., Levin, J., & Höglinger, G. U. (2026). A Biomarker‐Based Classification of Corticobasal Syndrome. Movement Disorders, 41(1), 129-142. https://doi.org/10.1002/mds.70070

Vancouver

Palleis C, Bernhardt AM, Weidinger E, Fietzek UM, Jäck A, Katzdobler S, et al. A Biomarker‐Based Classification of Corticobasal Syndrome. Movement Disorders. 2026;41(1):129-142. doi:10.1002/mds.70070

BibTeX
@article{Palleis2026,
  author = {Palleis, Carla and Bernhardt, Alexander Maximilian and Weidinger, Endy and Fietzek, Urban M and Jäck, Alexander and Katzdobler, Sabrina and Gnörich, Johannes and Bauer, Theresa and Franzmeier, Nicolai and Perneczky, Robert and German Imaging Initiative for Tauopathies (GII4T), German Imaging Initiative for Tauopathies (GII4T) and Brendel, Matthias and Levin, Johannes and Höglinger, Günter U},
  title = {A Biomarker‐Based Classification of Corticobasal Syndrome},
  journal = {Movement Disorders},
  year = {2026},
  volume = {41},
  number = {1},
  pages = {129--142},
  doi = {10.1002/mds.70070}
}
Kostenlos starten →